MCID: STV007
MIFTS: 46

Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Categories: Skin diseases, Rare diseases

Aliases & Classifications for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

MalaCards integrated aliases for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

Name: Stevens-Johnson Syndrome/toxic Epidermal Necrolysis 25
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 25 69
Drug-Induced Stevens Johnson Syndrome 25 69
Toxic Epidermal Necrolysis 25 69
Stevens-Johnson Syndrome 25 69
Mycoplasma-Induced Stevens Johnson Syndrome 25
Lyell's Syndrome 25
Lyell Syndrome 56

Characteristics:

Orphanet epidemiological data:

56
lyell syndrome
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare skin diseases


External Ids:

Orphanet 56 ORPHA537
UMLS via Orphanet 70 C0014518
ICD10 via Orphanet 34 L51.2

Summaries for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Genetics Home Reference : 25 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe skin reaction most often triggered by particular medications. Although Stevens-Johnson syndrome and toxic epidermal necrolysis were once thought to be separate conditions, they are now considered part of a continuum. Stevens-Johnson syndrome represents the less severe end of the disease spectrum, and toxic epidermal necrolysis represents the more severe end.

MalaCards based summary : Stevens-Johnson Syndrome/toxic Epidermal Necrolysis, also known as stevens-johnson syndrome toxic epidermal necrolysis spectrum, is related to systemic lupus erythematosus and hypersensitivity syndrome, carbamazepine-induced. An important gene associated with Stevens-Johnson Syndrome/toxic Epidermal Necrolysis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Etanercept and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Related Diseases for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 28.8 CCL5 CXCR3 IFNG IL2 TLR9
2 hypersensitivity syndrome, carbamazepine-induced 12.2
3 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 10.9 HLA-A HLA-B
4 ramsay hunt syndrome i 10.8 HLA-A HLA-B
5 cytoplasmic body myopathy 10.8 IL13 IL5
6 gastroschisis 10.7 IFNG IL5
7 bulbospinal polio 10.7 IFNG IL2
8 cardioskeletal syndrome, kuwaiti type 10.7 HLA-A HLA-B
9 erythema multiforme 10.7
10 lens-induced iridocyclitis 10.7 HLA-A HLA-B HLA-C
11 progressive myoclonus epilepsy 10.7 HLA-A HLA-B HLA-C
12 aortic arch interruption 10.7 IL13 IL5
13 heterotaxy, visceral, 4, autosomal 10.6 HLA-A HLA-B HLA-C
14 aseptic meningitis 10.6 CCL17 HLA-A HLA-B
15 autoimmune polyglandular syndrome type 3 10.6 IFNG IL2
16 acanthoma 10.6 HLA-A HLA-B IFNG
17 cholesteatoma of middle ear 10.6 IFNG IL13 IL5
18 classic hairy cell leukemia 10.6 HLA-A HLA-B HLA-C
19 acute gonococcal prostatitis 10.6 IFNG IL13 IL5
20 loiasis 10.6 IFNG IL13 IL5
21 acute contagious conjunctivitis 10.6 IFNG IL13 IL5
22 dioctophymiasis 10.6 IL13 IL2 IL5
23 indian tick typhus 10.6 CCL5 IFNG IL13
24 nonspecific interstitial pneumonia 10.6 CCL17 CCL22 IL5
25 papillary squamous carcinoma 10.6 CCL22 IFNG IL13
26 abnormal retinal correspondence 10.5 IFNG IL2 IL5
27 balkan nephropathy 10.5 IFNG IL13 IL5
28 prader-willi syndrome due to paternal deletion of 15q11q13 type 1 10.5 CCR3 CXCR3
29 acral lentiginous melanoma 10.5 HLA-B IFNG IL2
30 anthracosilicosis 10.5 IFNG IL2
31 pyridoxine-responsive sideroblastic anemia 10.5 CCL17 IFNG IL2
32 hypercementosis 10.5 CCL5 IL13 IL5
33 intestinal disaccharidase deficiency 10.5 HLA-A IFNG IL2
34 fibrous histiocytoma 10.5 CCL5 IFNG IL5
35 disease of mental health 10.5 CCL17 HLA-B IFNG IL5
36 trachea leiomyoma 10.5 CCL5 IL13 IL5
37 mazabraud syndrome 10.5 HLA-A HLA-B HLA-C IFNG
38 cranial nerve malignant neoplasm 10.5 CXCR3 IFNG IL13
39 burns 10.5
40 sezary's disease 10.4 HLA-A HLA-B IFNG IL2
41 conjunctival concretion 10.4 CCR3 IL13 IL5
42 graft-versus-host disease, protection against 10.4 IFNG IL2
43 18p deletion syndrome 10.4 CCL17 IL13 IL5
44 hernia of ovary and fallopian tube 10.4 HLA-A HLA-B
45 corneal intraepithelial neoplasm 10.4 IFNG IL13 IL2 IL5
46 uterus interstitial leiomyoma 10.4 IFNG IL13 IL2 IL5
47 cherry allergy 10.4 CCL17 CCL22 IL13 IL5
48 asphyxiating thoracic dystrophy 10.3 HLA-B IFNG IL13 IL2
49 scleral disease 10.3 IFNG IL13 IL2 IL5
50 female urethral cancer 10.3 CCL5 CCR3 IL5

Graphical network of the top 20 diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:



Diseases related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Symptoms & Phenotypes for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

GenomeRNAi Phenotypes related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.14 HLA-B HLA-A HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.14 HLA-C HLA-B HLA-A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.14 HLA-B HLA-A HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.14 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.14 HLA-B HLA-A HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.14 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.14 HLA-B HLA-A HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.14 HLA-B HLA-A HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.14 HLA-C HLA-B HLA-A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.14 HLA-B HLA-A HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 HLA-B HLA-A HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.14 HLA-C

MGI Mouse Phenotypes related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CCL5 CCR3 IL13 CXCR3 IL2 CXCR4
2 immune system MP:0005387 9.93 CCL5 CCR3 IL13 CXCR3 IL2 CXCR4
3 digestive/alimentary MP:0005381 9.92 IKZF1 IL13 IL2 CXCR4 IL5 TLR9
4 neoplasm MP:0002006 9.56 IKZF1 CXCR3 IL2 CXCR4 EPHX1 IL5
5 respiratory system MP:0005388 9.28 CCR3 IL13 CXCR3 IL2 CXCR4 IL5

Drugs & Therapeutics for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Drugs for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 3 185243-69-0
2
Coal tar Approved Phase 3 8007-45-2
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4 Antibodies Phase 3
5 gamma-Globulins Phase 3
6 Immunoglobulins Phase 3
7 Immunoglobulins, Intravenous Phase 3
8 Rho(D) Immune Globulin Phase 3
9 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
10 Antirheumatic Agents Phase 3,Phase 1,Phase 2
11 Dermatologic Agents Phase 3,Phase 1,Phase 2
12 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
13 Analgesics Phase 3
14 Analgesics, Non-Narcotic Phase 3
15 Antifungal Agents Phase 3
16 Anti-Infective Agents Phase 3
17 Anti-Inflammatory Agents, Non-Steroidal Phase 3
18 Calcineurin Inhibitors Phase 3
19 Cyclosporins Phase 3
20 Emollients Phase 3
21 Immunosuppressive Agents Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Pharmaceutical Solutions Phase 3
24
Petrolatum Approved Phase 1, Phase 2 8009-03-8
25
Infliximab Approved Phase 1, Phase 2 170277-31-3
26
Clobetasol Investigational Phase 1, Phase 2 25122-46-7, 25122-41-2 32798 5311051
27 glucocorticoids Phase 1, Phase 2
28 Hormone Antagonists Phase 1, Phase 2
29 Hormones Phase 1, Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
31
Isotretinoin Approved 4759-48-2 5538 5282379
32
Eslicarbazepine acetate Approved 75970-99-9, 236395-14-5 123618
33
Carbamazepine Approved, Investigational 298-46-4 2554
34 Diuretics, Potassium Sparing
35 Sodium Channel Blockers
36 Liver Extracts
37 Anticonvulsants

Interventional clinical trials:

(show all 16)

id Name Status NCT ID Phase Drugs
1 G-CSF in the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
2 Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
3 Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
4 Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Recruiting NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
5 Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
6 Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
7 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
8 Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
9 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
10 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions Unknown status NCT01276314 anti-TNF a
11 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
12 Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Recruiting NCT03176342
13 Severe Cutaneous Adverse Reactions in Thailand Recruiting NCT02574988
14 An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
15 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction. Not yet recruiting NCT03166241
16 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions Not yet recruiting NCT03184597

Search NIH Clinical Center for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Genetic Tests for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Anatomical Context for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

MalaCards organs/tissues related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

39
Skin, Liver, T Cells, Eye, Testes

Publications for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Articles related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis:

(show top 50) (show all 87)
id Title Authors Year
1
Genetics and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: What Have We Learned? ( 28278317 )
2017
2
Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. ( 27717620 )
2017
3
Letter to the Editor concerning the article "Long term complications of Stevens-Johnson syndrome/Toxic epidermal necrolysis: The spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multi-disciplinary follow up. ( 28626892 )
2017
4
Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. ( 28108296 )
2017
5
"Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/Toxic Epidermal Necrolysis patients from a Swedish Burn Center". ( 28075032 )
2017
6
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Induced by Fexofenadine. ( 28570227 )
2017
7
What's beneath the surface? Stevens-Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report. ( 28072947 )
2017
8
Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. ( 28940568 )
2017
9
Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. ( 28144971 )
2017
10
Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study. ( 28366923 )
2017
11
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report. ( 28488978 )
2017
12
Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. ( 28084616 )
2017
13
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. ( 27287213 )
2016
14
Validation of a novel real-time PCR assay for detection of HLA-B*15:02 allele for prevention of carbamazepine - Induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in individuals of Asian ancestry. ( 27544047 )
2016
15
Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 28011147 )
2016
16
Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. ( 26882981 )
2016
17
A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. ( 26847613 )
2016
18
Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. ( 27679410 )
2016
19
A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. ( 27652522 )
2016
20
Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. ( 26582440 )
2016
21
Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. ( 27130345 )
2016
22
Stevens-Johnson syndrome/toxic epidermal necrolysis caused by cefadroxil in a cat. ( 28491426 )
2016
23
Fulminating Course of Drug Reaction with Eosinophilia and Systemic Symptoms exacerbated by a Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis overlap. ( 27430091 )
2016
24
Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. ( 27716721 )
2016
25
Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey. ( 26810444 )
2016
26
Commissioning of a specialist service for Stevens-Johnson syndrome/toxic epidermal necrolysis: current management in England could be improved. ( 27106856 )
2016
27
U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. ( 27317286 )
2016
28
Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. ( 27898730 )
2016
29
Stevens Johnson syndrome/toxic epidermal necrolysis after exogenous contact to S,S-dimethyl cyanoimidodithiocarbonate. ( 27401191 )
2016
30
Stevens Johnson syndrome/toxic epidermal necrolysis-overlap, induced by lacosamide. ( 27017922 )
2016
31
Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 26488421 )
2015
32
HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. ( 24871931 )
2015
33
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Should be in Mind in Children with Febrile Neutropenia, Oral Cavity Lesions, and Skin Rash. ( 26376920 )
2015
34
HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. ( 25918017 )
2015
35
Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 26433536 )
2015
36
Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. ( 25005569 )
2015
37
Drug-induced liver injury Associated with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Patient Characteristics, Causes and Outcome in 36 Cases. ( 26439084 )
2015
38
Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities. ( 25547780 )
2015
39
Ocular manifestation, complications and aetiological factors in Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 25831677 )
2015
40
IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. ( 25672763 )
2015
41
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. I. Systemic Disease. ( 26549248 )
2015
42
Extracutaneous manifestations and long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 25660673 )
2015
43
Systemic lupus erythematosus presenting as Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 24662561 )
2014
44
Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. ( 24388722 )
2014
45
Beneficial therapeutic effects of hemoperfusion in the treatment of severe Stevens-Johnson syndrome/toxic epidermal necrolysis: preliminary results. ( 25535143 )
2014
46
Recurrent blisters in a case of resolving Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 25382518 )
2014
47
Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. ( 25087214 )
2014
48
Association of ABCB1,A CYP3A4,A EPHX1,A FAS,A SCN1A,A MICA, andA BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. ( 24861996 )
2014
49
Prosthetic Replacement of the Ocular Surface Ecosystem as Treatment for Ocular Surface Disease in Patients with a History of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. ( 25282251 )
2014
50
Steroids in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Current Evidence and Implications for Future Research. ( 25406459 )
2014

Variations for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Expression for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Search GEO for disease gene expression data for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis.

Pathways for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Pathways related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
2
Show member pathways
13.6 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
3
Show member pathways
13.53 CCL17 CCL22 CCL5 CXCR4 F2RL2 IFNG
4
Show member pathways
13.33 CCL22 CCL5 HLA-A HLA-B HLA-C IFNG
5
Show member pathways
13.29 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
6
Show member pathways
13.22 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
7
Show member pathways
12.85 CCL5 FAS IFNG IL2 TLR9
8
Show member pathways
12.84 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
9
Show member pathways
12.72 CXCR4 FAS HLA-A HLA-B HLA-C IFNG
10
Show member pathways
12.6 CCL5 FAS HLA-A HLA-B HLA-C IFNG
11
Show member pathways
12.49 FAS HLA-A HLA-B HLA-C IFNG IL2
12 12.47 CCL5 CXCR4 FAS IFNG IKZF1 IL2
13
Show member pathways
12.4 FAS IFNG IL2 IL5
14 12.4 HLA-A HLA-B HLA-C IL2
15 12.4 CXCR4 HLA-A HLA-B HLA-C
16
Show member pathways
12.31 CCL17 IFNG IL13 IL5
17 12.28 HLA-A HLA-B HLA-C IFNG
18 12.27 CCR3 HLA-A HLA-B HLA-C
19
Show member pathways
12.2 IFNG IL13 IL2 IL5
20
Show member pathways
12.02 IL13 IL2 IL5 TLR9
21 11.98 CCR3 IFNG IL2 IL5
22
Show member pathways
11.94 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
23
Show member pathways
11.9 IFNG IL2 TLR9
24 11.81 IFNG IL13 IL2 IL5
25
Show member pathways
11.77 IFNG IKZF1 IL2 IL5
26 11.76 IFNG IKZF1 IL2 TLR9
27
Show member pathways
11.71 HLA-A HLA-B HLA-C IFNG IL13 IL2
28 11.66 CCL5 CCR3 IL13 IL5
29
Show member pathways
11.62 HLA-A IFNG IL2
30 11.54 FAS IFNG IL2
31 11.54 CXCR3 IFNG IKZF1 IL13 IL2 IL5
32 11.52 CCL22 CCL5 IL13
33 11.5 CXCR4 IKZF1 IL5
34
Show member pathways
11.42 FAS IFNG IL2
35 11.35 FAS IFNG TLR9
36 11.32 IFNG IL2 IL5
37 11.3 IFNG IL13 IL5
38 11.29 IFNG IL13 IL2 IL5
39 11.23 IFNG IL13 IL2
40 11.2 CCL17 CCL22 CCL5 IL13 IL2 IL5
41 11.19 IFNG IL13 IL2 IL5
42 11.17 HLA-A HLA-B HLA-C
43 10.86 IL13 IL5
44 10.77 CCL17 CCL22 IFNG IL13 IL2 IL5

GO Terms for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

Cellular components related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CCL17 CCL22 CCL5 F2RL2 FAS IFNG
2 external side of plasma membrane GO:0009897 9.76 CXCR3 FAS IFNG IL13
3 cell surface GO:0009986 9.73 CXCR3 CXCR4 FAS HLA-A HLA-B HLA-C
4 phagocytic vesicle membrane GO:0030670 9.58 HLA-A HLA-B HLA-C
5 recycling endosome membrane GO:0055038 9.54 HLA-A HLA-B HLA-C
6 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-A HLA-B HLA-C
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-C
8 MHC class I protein complex GO:0042612 8.8 HLA-A HLA-B HLA-C
9 extracellular space GO:0005615 10.03 CCL17 CCL22 CCL5 IFNG IL13 IL2

Biological processes related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.95 CCL17 CCL22 CCL5 IL13 IL2
2 regulation of immune response GO:0050776 9.89 HLA-A HLA-B HLA-C IFNG
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.86 CCR3 CXCR3 CXCR4 IL2
4 response to toxic substance GO:0009636 9.83 CCL5 EPHX1 FAS
5 response to virus GO:0009615 9.83 CCL22 CCL5 CXCR4 IFNG
6 movement of cell or subcellular component GO:0006928 9.82 CXCR3 IFNG IL13
7 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.81 HLA-A HLA-B HLA-C
8 cellular response to interleukin-1 GO:0071347 9.8 CCL17 CCL22 CCL5
9 type I interferon signaling pathway GO:0060337 9.79 HLA-A HLA-B HLA-C
10 interferon-gamma-mediated signaling pathway GO:0060333 9.78 HLA-A HLA-B HLA-C IFNG
11 positive regulation of T cell proliferation GO:0042102 9.77 CCL5 IFNG IL2
12 cellular response to interferon-gamma GO:0071346 9.76 CCL17 CCL22 CCL5
13 neutrophil chemotaxis GO:0030593 9.76 CCL17 CCL22 CCL5 IFNG
14 monocyte chemotaxis GO:0002548 9.74 CCL17 CCL22 CCL5
15 chemotaxis GO:0006935 9.73 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
16 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.69 HLA-A HLA-B HLA-C
17 antigen processing and presentation GO:0019882 9.67 HLA-A HLA-B HLA-C IFNG
18 dendritic cell chemotaxis GO:0002407 9.65 CCL5 CXCR4
19 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL2 IL5
20 inflammatory response GO:0006954 9.65 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
21 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IFNG IL2
22 chemokine-mediated signaling pathway GO:0070098 9.63 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 CCL5 IFNG IL2
24 protection from natural killer cell mediated cytotoxicity GO:0042270 9.58 HLA-A HLA-B
25 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.58 HLA-A HLA-B HLA-C
26 inflammatory cell apoptotic process GO:0006925 9.54 FAS IFNG
27 positive regulation of B cell proliferation GO:0030890 9.5 IL13 IL2 IL5
28 immune response GO:0006955 9.36 CCL17 CCL22 CCL5 FAS HLA-A HLA-B
29 positive regulation of immunoglobulin production GO:0002639 9.32 IL13
30 G-protein coupled receptor signaling pathway GO:0007186 10.1 CCL17 CCL22 CCL5 CCR3 CXCR3 CXCR4
31 immune system process GO:0002376 10.04 HLA-A HLA-B HLA-C IL2 TLR9
32 viral process GO:0016032 10 CCR3 CXCR4 HLA-A HLA-B HLA-C

Molecular functions related to Stevens-Johnson Syndrome/toxic Epidermal Necrolysis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.77 CCR3 CXCR3 CXCR4 F2RL2 FAS
2 chemokine activity GO:0008009 9.5 CCL17 CCL22 CCL5
3 C-C chemokine binding GO:0019957 9.43 CCR3 CXCR4
4 peptide antigen binding GO:0042605 9.43 HLA-A HLA-B HLA-C
5 C-X-C chemokine receptor activity GO:0016494 9.4 CXCR3 CXCR4
6 cytokine activity GO:0005125 9.17 CCL17 CCL22 CCL5 IFNG IL13 IL2
7 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5
8 chemokine receptor activity GO:0004950 9.13 CCR3 CXCR3 CXCR4

Sources for Stevens-Johnson Syndrome/toxic Epidermal Necrolysis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....